Novartis hikes 2019 outlook as gene therapy, skin drugs shine
Share:
ZURICH (Reuters) - Novartis on Tuesday boosted its full-year targets, as sales of medicines including psoriasis drug Cosentyx and gene therapy Zolgensma helped the Swiss drugmaker surpass analysts' third-quarter expectations.Sales are now seen growing at a high single-digit percentage rate at constant currencies, from the mid-to-high single digit rate forecast from July. Core operating income is now seen growing at a mid- to high-teen rate, up from low double-digit to mid-teen percentages...